+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Copper(II)-selective chelation improves function and antioxidant defences in cardiovascular tissues of rats as a model of diabetes: comparisons between triethylenetetramine and three less copper-selective transition-metal-targeted treatments



Copper(II)-selective chelation improves function and antioxidant defences in cardiovascular tissues of rats as a model of diabetes: comparisons between triethylenetetramine and three less copper-selective transition-metal-targeted treatments



Diabetologia 53(6): 1217-1226



Treatment with the Cu(II)-selective chelator triethylenetetramine (TETA) improves cardiovascular disease in human patients, and cardiac and vascular/renal disease in rats used as a model of diabetes. Here we tested two hypotheses: first, that TETA elicits greater improvement in organ function than less Cu-selective transition-metal-targeted treatments; second, that the therapeutic actions of TETA are consistent with mediation through suppression of oxidative stress. Rats were made diabetic with streptozotocin (55 mg/kg, i. v.) and treated from 8 weeks after disease induction for the following 8 weeks with effective dosages of oral TETA, or one of three less Cu-selective transition-metal-targeted treatments: D-penicillamine, deferiprone or Zn acetate. Treatment effects were measured in ex vivo cardiac and aortic tissues, plasma and urine. Diabetes damaged both cardiac and renal/vascular function by impairing the ability of cardiac output to respond physiologically to rising afterload, and by significantly elevating the urinary albumin/creatinine ratio. Diabetes also lowered total antioxidant potential and heparan sulphate levels in cardiac and arterial tissues, and serum ferroxidase activity, whereas it elevated urinary heparan sulphate excretion. TETA treatment rectified or partially rectified all these defects, whereas the other three experimental treatments were ineffectual. By contrast, none of the four drug treatments lowered diabetes-mediated elevations of plasma glucose or lipid concentrations. TETA may limit the cardiac and renal/vascular damage inflicted by diabetes through its actions to reinforce antioxidant defence mechanisms, probably acting through selective chelation of 'loosely-bound'/chelatable Cu(II). It may also improve heparan sulphate homeostasis and bolster antioxidant defence by increasing vascular extracellular superoxide dismutase activity. Urinary albumin/creatinine ratio might prove useful for monitoring TETA treatment.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 052345456

Download citation: RISBibTeXText

PMID: 20221822

DOI: 10.1007/s00125-010-1698-8


Related references

Demonstration of a hyperglycemia-driven pathogenic abnormality of copper homeostasis in diabetes and its reversibility by selective chelation: quantitative comparisons between the biology of copper and eight other nutritionally essential elements in normal and diabetic individuals. Diabetes 54(5): 1468-1476, 2005

Regeneration of the heart in diabetes by selective copper chelation. Diabetes 53(9): 2501-2508, 2004

Selective divalent copper chelation for the treatment of diabetes mellitus. Current Medicinal Chemistry 19(17): 2828-2860, 2012

Selective Divalent Copper Chelation for the Treatment of Diabetes Mellitus. Current Medicinal Chemistry 19(17): 2828-2860, 2012

Therapeutic potential of copper chelation with triethylenetetramine in managing diabetes mellitus and Alzheimer's disease. Drugs 71(10): 1281-1320, 2011

Highly sensitive and selective fluorescence detection of copper (II) ion based on multi-ligand metal chelation. Talanta 126: 185-190, 2014

A copper(II)-selective chelator ameliorates diabetes-evoked renal fibrosis and albuminuria, and suppresses pathogenic TGF-beta activation in the kidneys of rats used as a model of diabetes. Diabetologia 51(9): 1741-1751, 2008

Quantitative proteomic profiling identifies new renal targets of copper(II)-selective chelation in the reversal of diabetic nephropathy in rats. Proteomics 9(18): 4309-4320, 2009

Cadmium and/or copper excess induce interdependent metal accumulation, DNA methylation, induction of metal chelators and antioxidant defences in the seagrass Zostera marina. Chemosphere 224: 111-119, 2019

Selective imidazolidine ring opening during complex formation of iron(III), copper(II), and zinc(II) with a multidentate ligand obtained from 2-pyridinecarboxaldehyde N-oxide and triethylenetetramine. Inorganic Chemistry 39(15): 3205-3212, 2000

The disastrous copper. Comparing extraction and chelation treatments to face the threat of copper-containing inks on cellulose. Carbohydrate Polymers 206: 198-209, 2019

Copper(I) electrode function of two types of copper(II) ion-selective electrodes. Talanta 32(8 Pt 1): 654-656, 1985

Metal binding in chelation therapy x ray crystal structure of a copper i copper ii complex of d penicillamine. Journal of the Chemical Society Chemical Communications (9): 312-313, 1976

Copper-Driven Deselenization: A Strategy for Selective Conversion of Copper Ion to Nanozyme and Its Implication for Copper-Related Disorders. Acs Applied Materials and Interfaces 11(5): 4766-4776, 2019

The behaviour of a copper ii ion selective electrode in seawater copper consumption capacity and copper determinations. Marine Chemistry 38(3-4): 165-184, 1992